Bullfrog AI Holdings shares surge 60.00% intraday after securing partnership with top-five global pharmaceutical company to accelerate MDD drug discovery using its bfLEAP platform.
ByAinvest
Tuesday, Mar 31, 2026 10:06 am ET1min read
BFRG--
Bullfrog AI Holdings surged 60.00% intraday, as the company announced a commercial agreement with one of the world's top five pharmaceutical firms. Under the deal, the firm will use its proprietary bfLEAP platform to identify and prioritize new drug targets for major depressive disorder (MDD), accelerating the client's drug discovery and clinical development. The agreement grants the client exclusive rights to the candidate targets and secures access to the MDD market, which exceeded $8 billion in 2025 and is projected to surpass $11 billion by 2032.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet